Q-omics provides the consensus-scored PCDHB7 profile across patient tissues and cancer cell-line models. PCDHB7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHB7 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, PCDHB7 protein abundance shows 25,013 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KICH, and LSCC as cancer lineages where PCDHB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB7 survival associations across molecular data types. PCDHB7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB7 RNA expression–survival associations across cancer types. High PCDHB7 expression shows unfavorable associations in BLCA, LGG, ACC, COAD and HNSC, but favorable associations in UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHB7 RNA expression.
This table summarizes PCDHB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDHB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB7 shows lower tumor expression in KICH, THCA, UCEC, BRCA and LUAD and higher tumor expression in HNSC. The KICH box plot shows higher PCDHB7 RNA expression in normal versus tumor tissue (log2 FC = −1.646, t-test p < 0.001).
This table shows molecular features associated with PCDHB7 in patient tissues and cancer cell lines. In patient samples, PCDHB7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
